Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | F7 | P08709 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7932470 | 0.84 | L3MBTL1 (0.54) | ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL10066478 | 0.84 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2POLBNPSR1LMNA | |
| SCHEMBL1697719 | 0.84 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2POLBNPSR1LMNA | |
| SCHEMBL2178915 | 0.84 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2POLBNPSR1LMNA | |
| SCHEMBL9953212 | 0.84 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2POLBNPSR1LMNA | |
| SCHEMBL1697716 | 0.84 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2POLBNPSR1LMNA | |
| SCHEMBL7932227 | 0.83 | GPR139 (0.54) | ALDH1A1SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL5473681 | 0.80 | SMN1; SMN2 (0.64) | ALDH1A1SMN1; SMN2POLBLMNACYP1A2 | |
| SCHEMBL619526 | 0.78 | SMN1; SMN2 (0.67) | ALDH1A1SMN1; SMN2POLBLMNACYP1A2 | |
| SCHEMBL255663 | 0.78 | CYP1A2 (0.71) | ALDH1A1SMN1; SMN2POLBLMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| WO-2010033360-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | 1/3 ABSOLUTE SCIENCE, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009045761-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | ABSOLUTE SCIENCE, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | MMP7, MMP3, MMP9 | ALDH1A1 496/4885SMN1; SMN2 313/4885POLB 1320/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | ALDH1A1 2213/4885SMN1; SMN2 120/4885POLB 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.